LY2812223 is primarily investigated for its potential therapeutic applications in the treatment of various diseases, particularly in the field of oncology. It is being studied as a targeted therapy to inhibit specific pathways involved in cancer cell growth and proliferation. Researchers are exploring its efficacy in preclinical and clinical trials to determine its ability to suppress tumor progression and improve patient outcomes. Additionally, LY2812223 is being evaluated for its role in combination therapies, where it may enhance the effects of other anticancer agents. Its application extends to understanding molecular mechanisms in disease models, contributing to the development of novel treatment strategies.